HER2 status-Positive Posts on Medivizor
Navigation Menu

HER2 status-Positive Posts on Medivizor

Adding pertuzumab to treatment in breast cancer

Posted by on Dec 4, 2018 in Breast cancer | 0 comments

In a nutshell This study wanted to find out which treatment is better for breast cancer, chemotherapy plus trastuzumab (Herceptin) and surgery, or pertuzumab (Perjeta), and chemotherapy plus trastuzumab (Herceptin) and surgery. The study found that adding pertuzumab to the standard treatment worked better to completely remove all signs of cancer compared...

Read More

Comparison of lapatinib and trastuzumab in patients with HER-2 receptor positive breast cancer

Posted by on Jul 2, 2018 in Breast cancer | 0 comments

In a nutshell This study aimed to compare lapatinib (Tykerb) and trastuzumab (Herceptin) in patients with HER-2 receptor positive breast cancer. This study found that in patients with hormone receptor-positive tumors, use of lapatinib for 6 months, followed by trastuzumab for 12 months significantly improved survival...

Read More

The effect of delaying trastuzumab therapy

Posted by on Jun 6, 2016 in Breast cancer | 0 comments

In a nutshell This study investigated the effect of delaying trastuzumab (Herceptin) therapy in patients with breast cancer. The study concluded that delays in receiving trastuzumab therapy of 6 months or more leads to decreased overall survival and relapse-free survival time. Some background Some breast cancers depend on the human epidermal...

Read More

Can pertuzumab improve long-term response rates in HER2-positive breast cancer?

Posted by on Mar 14, 2016 in Breast cancer | 0 comments

In a nutshell The authors aimed to assess whether adding pertuzumab (Perjeta) to chemotherapy could improve response in women with metastatic (has spread) breast cancer. This study showed that adding pertuzumab to chemotherapy resulted in higher response rates among women with breast cancer that relied on the human epidermal growth factor 2 (HER2) to...

Read More

Combining targeted therapies: the benefits of directly targeting HER2+ breast cancer

Posted by on Oct 10, 2015 in Breast cancer | 0 comments

In a nutshell The authors aimed to determine the effectiveness of targeted treatments and also compared combination therapies. Some background HER2 positive breast cancer is associated with the over-expression (production) of the human epidermal growth factor receptor 2 (HER2+). HER2+ breast cancer is known to be more aggressive with a poorer...

Read More

Retargeting: Treatment for metastatic HER2+ breast cancer that has progressed following targeted treatment

Posted by on Jul 18, 2015 in Breast cancer | 0 comments

In a nutshell The authors reviewed the benefits and safety of ado–trastuzumab emtansine (Kadcyla), a treatment for metastatic breast cancer (cancer that has spread to other areas of the body). Some background Human epidermal growth factor receptor 2 positive (HER2) breast cancer depends on HER2 for growth. Treatments that target the HER2...

Read More